Depression Symptoms Reduced by Drug in New Clinical Trial

A single dose of dimethyltryptamine (DMT), a psychedelic compound, combined with psychological support, has shown promising results in rapidly reducing symptoms of major depressive disorder, according to recent clinical trials. The findings, published in February 2025 in the journal Nature, suggest a potential new avenue for treating individuals who haven’t responded adequately to conventional therapies.

DMT and Depression: A Novel Approach

Major depressive disorder affects millions worldwide and remains a significant public health challenge. Current treatments, including antidepressants and psychotherapy, are effective for many, but a substantial number of patients experience persistent symptoms despite these interventions. This is often referred to as treatment-resistant depression (TRD).

DMT is a naturally occurring psychedelic substance found in various plants and animals, and is the psychoactive ingredient in the brew ayahuasca. Researchers have been increasingly exploring the therapeutic potential of psychedelics, including DMT and psilocybin (found in “magic mushrooms”), for mental health conditions. The mechanism by which DMT exerts its antidepressant effects isn’t fully understood, but experts believe it may involve disrupting negative thought patterns and promoting neuroplasticity – the brain’s ability to reorganize itself by forming new neural connections.

“DMT probably works for depression by taking you out of your downhill spiral while at the same time altering brain chemistry in a way to promote the release of hormones, especially serotonin, but also dopamine,” explained Dr. Marc Siegel, a Fox News senior medical analyst, who was not involved in the recent study. This suggests a multifaceted impact on brain function, potentially addressing both the emotional and biological components of depression.

Study Details and Findings

The phase IIa, double-blind, placebo-controlled, randomized clinical trial, led by researchers at Imperial College London, involved 34 adults diagnosed with moderate-to-severe major depressive disorder. Participants received either a single 21.5-mg dose of DMT administered intravenously or a placebo, alongside supportive psychotherapeutic care. The primary outcome measure was the change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores at two weeks post-treatment.

The results demonstrated a significantly greater reduction in MADRS scores in the DMT group compared to the placebo group (mean difference = −7.35; 95% CI = −13.62 to −1.08; P = 0.023). This indicates a statistically significant improvement in depressive symptoms among those who received DMT. An open-label phase of the study, where all participants were offered a second DMT dose, showed that the antidepressant effects persisted for up to three months, with no significant difference observed between those receiving one versus two doses.

Importantly, the treatment was generally well-tolerated. Adverse events reported were mostly mild to moderate, including infusion site pain, nausea, and transient anxiety. No serious adverse events were recorded during the trial.

Other Psychedelic Research

The research into psychedelics for mental health extends beyond DMT. A recent study highlighted by Fox News indicated that a single dose of psychedelics, in general, can significantly reduce symptoms of major depressive disorder, with effects lasting up to six months. Compass Pathways is reporting positive results with their psilocybin-based therapy, COMP360, for severe depression, with a February 17, 2026 announcement detailing a 3.6-point greater decrease in depression scores compared to a control group.

What This Means for Patients

While these findings are encouraging, it’s crucial to emphasize that DMT is not currently an approved treatment for depression. The research is still in its early stages, and further studies are needed to confirm these results, optimize dosage, and assess long-term safety and efficacy. The trials conducted thus far have involved carefully controlled settings with psychological support, which is a critical component of the treatment approach.

The use of psychedelics carries potential risks, and self-medication is strongly discouraged. Individuals considering psychedelic therapy should only do so within the context of a clinical trial or under the guidance of qualified healthcare professionals. The legal status of DMT varies widely, and it remains a controlled substance in many jurisdictions.

The emerging research on DMT and other psychedelics represents a potentially transformative shift in the treatment of depression. However, responsible and rigorous scientific investigation is essential to ensure that these therapies are developed and implemented safely and effectively, offering hope to those who have not found relief through traditional methods.